TY  - JOUR
A1  - Mühlenbruch, Lena
A1  - Abou-Kors, Tsima
A1  - Dubbelaar, Marissa L.
A1  - Bichmann, Leon
A1  - Kohlbacher, Oliver
A1  - Bens, Martin
A1  - Thomas, Jaya
A1  - Ezić, Jasmin
A1  - Kraus, Johann M.
A1  - Kestler, Hans A.
A1  - von Witzleben, Adrian
A1  - Mytilineos, Joannis
A1  - Fürst, Daniel
A1  - Engelhardt, Daphne
A1  - Döscher, Johannes
A1  - Greve, Jens
A1  - Schuler, Patrick J.
A1  - Theodoraki, Marie-Nicole
A1  - Brunner, Cornelia
A1  - Hoffmann, Thomas K.
A1  - Rammensee, Hans-Georg
A1  - Walz, Juliane S.
A1  - Laban, Simon
T1  - The HLA ligandome of oropharyngeal squamous cell carcinomas reveals shared tumour-exclusive peptides for semi-personalised vaccination
T2  - British Journal of Cancer
N2  - Background
The immune peptidome of OPSCC has not previously been studied. Cancer-antigen specific vaccination may improve clinical outcome and efficacy of immune checkpoint inhibitors such as PD1/PD-L1 antibodies.

Methods
Mapping of the OPSCC HLA ligandome was performed by mass spectrometry (MS) based analysis of naturally presented HLA ligands isolated from tumour tissue samples (n = 40) using immunoaffinity purification. The cohort included 22 HPV-positive (primarily HPV-16) and 18 HPV-negative samples. A benign reference dataset comprised of the HLA ligandomes of benign haematological and tissue datasets was used to identify tumour-associated antigens.

Results
MS analysis led to the identification of naturally HLA-presented peptides in OPSCC tumour tissue. In total, 22,769 peptides from 9485 source proteins were detected on HLA class I. For HLA class II, 15,203 peptides from 4634 source proteins were discovered. By comparative profiling against the benign HLA ligandomic datasets, 29 OPSCC-associated HLA class I ligands covering 11 different HLA allotypes and nine HLA class II ligands were selected to create a peptide warehouse.

Conclusion
Tumour-associated peptides are HLA-presented on the cell surfaces of OPSCCs. The established warehouse of OPSCC-associated peptides can be used for downstream immunogenicity testing and peptide-based immunotherapy in (semi)personalised strategies.
KW  - Cancer Research
KW  - Oncology
Y1  - 2023
UR  - https://opus.bibliothek.uni-augsburg.de/opus4/frontdoor/index/index/docId/106429
UR  - https://nbn-resolving.org/urn:nbn:de:bvb:384-opus4-1064297
SN  - 0007-0920
SN  - 1532-1827
VL  - 128
IS  - 9
SP  - 1777
EP  - 1787
PB  - Springer
CY  - Berlin
ER  -